공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

델타 유사 단백질 4 : 파이프라인 리뷰

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 09월 상품 코드 374383
페이지 정보 영문 51 Pages
가격
US $ 3,500 ₩ 3,979,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 7,958,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 11,937,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


델타 유사 단백질 4 : 파이프라인 리뷰 Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016
발행일 : 2016년 09월 페이지 정보 : 영문 51 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

델타 유사 단백질 4(Delta Like Protein 4)를 표적으로 한 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

델타 유사 단백질 4 개요

치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 영역별
  • 개발중인 제품 : 증상별

파이프라인 제품 개요

  • 후기 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

치료제 평가

  • 단독치료 제품(Monotherapy Products)/병용요법 제품(Combination Products)별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • AbbVie Inc
  • OncoMed Pharmaceuticals, Inc.
  • PharmAbcine, Inc.
  • Sevion Therapeutics, Inc.

약제 개요

휴지 상태인 프로젝트

개발이 중지된 제품

주요 뉴스 및 프레스 릴리스

부록

도표

LSH 16.10.24

Summary:

Global Markets Direct's, 'Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016', provides in depth analysis on Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted pipeline therapeutics.

The report provides comprehensive information on the Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4)
  • The report reviews Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Overview
  • Therapeutics Development
    • Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Products under Development by Stage of Development
    • Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Products under Development by Therapy Area
    • Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Products under Development by Indication
  • Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Products under Development by Companies
  • Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • OncoMed Pharmaceuticals, Inc.
    • PharmAbcine, Inc.
    • Sevion Therapeutics, Inc.
  • Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Drug Profiles
    • ABT-165 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • demcizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit DLL4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit DLL4 for Oncology and Inflammatory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMP-305B83 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMC-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Dormant Projects
  • Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Discontinued Products
  • Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Featured News & Press Releases
    • Sep 01, 2016: OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer
    • Jun 05, 2016: OncoMed Presents Phase 1b Data on demcizumab at the 2016 ASCO Annual Meeting
    • May 18, 2016: AbbVie To Present Data on ABT-165 at ASCO 2016
    • Apr 21, 2016: OncoMed Announces Clinical Data for Demcizumab to be Presented at the 2016 ASCO Annual Meeting
    • Apr 20, 2016: OncoMed Presents Demcizumab Mechanism Data at the AACR Annual Meeting 2016
    • Mar 17, 2016: OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab (anti-PD1)
    • Jan 22, 2016: OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers Symposium
    • Nov 09, 2015: OncoMed Presents Data From Anti-DLL4/VEGF Bispecific Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    • Nov 07, 2015: OncoMed Presents Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at the Society for Immunotherapy of Cancer Annual Meeting
    • Nov 04, 2015: OncoMed to Present Preclinical Data for the Combination of anti-DLL4/VEGF Bispecific plus anti-PD1 at the Society of Immunotherapy for Cancer Meeting
    • Oct 27, 2015: OncoMed to present preclinical results from OMP-305B83 at the AACR-NCI-EORTC International Conference
    • Aug 10, 2015: OncoMed Pharmaceuticals Updates Demcizumab Phase 1b Non-Small Cell Lung Cancer Survival Data
    • Jun 01, 2015: OncoMed Presents Data From Phase 1b Trial of Demcizumab in Pancreatic Cancer at the 2015 ASCO Annual Meeting
    • Jun 01, 2015: OncoMed Presents Updated Demcizumab Data in Non-Small Cell Lung Cancer at the 2015 ASCO Annual Meeting
    • May 28, 2015: OncoMed Pharmaceuticals to Review Key ASCO Data for Demcizumab During Conference Call on Tuesday, June 2, 2015
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by AbbVie Inc, H2 2016
  • Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016
  • Pipeline by PharmAbcine, Inc., H2 2016
  • Pipeline by Sevion Therapeutics, Inc., H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top
전화 문의
F A Q